Quantcast

Gemin X Announces Data Presentation for Its Novel, Targeted Cancer Therapy Obatoclax at the 26th Chemotherapy Foundation Symposium

October 31, 2008

Gemin X Pharmaceuticals announced today that clinical data from a Phase 1/2 study of obatoclax (GX15-070), the Company’s innovative pan Bcl-2 inhibitor, will be presented during The 26th Chemotherapy Foundation Symposium being held in New York City from November 4 – 8, 2008.

 Program Title:          Phase 1/2 Study Of Docetaxel Plus Obatoclax in Relapsed NSCLC Presenter:              Alberto A. Chiappori, MD Assistant Member Thoracic Oncology, Experimental Therapeutics H. Lee Moffitt Cancer Center, Tampa, Florida Program Date/Time:      Friday, November 7, 2008, 11:20 a.m. ET 

The Chemotherapy Foundation Symposium is hosted by the Chemotherapy Foundation, a non-profit organization dedicated to the control, cure and prevention of cancer through innovative medical therapies, and provides crucial seed money to gifted researchers to start groundbreaking work designed to facilitate breakthrough science. The Foundation’s programs are widely recognized in the field for their significant contributions to improved patient-care management and survival.

About Gemin X Pharmaceuticals

Gemin X Pharmaceuticals is dedicated to the discovery, development and commercialization of novel, targeted cancer therapeutics to improve the lives of patients. Gemin X is developing first-in-class cancer therapeutics based on reinitiating programmed cell death, or apoptosis, and the inhibition of metabolism in cancerous cells. Gemin X currently has three clinical development programs underway, ranging from Phase 2 clinical trials for its lead product candidates obatoclax (GX15-070), an innovative pan Bcl-2 inhibitor, and GMX1777, a novel inhibitor of NAD+ synthesis, to preclinical studies for its Telomere Capping program. Potential treatment indications for the full scope of pipeline programs span a broad range of hematological and solid tumors, including elderly acute myeloid leukemia (AML), mantle cell lymphoma (MCL), melanoma, glioblastoma, small cell lung cancer (SCLC), refractory acute lymphoblastic leukemia (ALL) and mastocytosis. Founded in 1998, Gemin X is privately held with drug development and executive headquarters in Malvern, Pennsylvania and drug discovery operations in Montreal, Canada. For more information, please visit www.geminx.com.




comments powered by Disqus